retatrutide type 2 diabetes trial results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide just delivered the first

External resources New England Journal of Medicine: Retatrutide Phase 2 Trial Results FDA Drug Safety and Availability Information For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol tools, and a community of thousands who have navigated these exact dosing decisions

Prevalence of childhood and adult obesity in the United States, 2011-2012

Let's figure out what your metabolism needs, choose the right medication for your body, and build a plan that finally works

Patients are considered for bariatric surgery if their body mass index is at least 40, or at least 35 if accompanied by conditions such as diabetes or hypertension

That process does not happen overnight

Even after reaching a target weight, many patients continue semaglutide often at a smaller dose to support chronic weight management and keep the weight off